Liquid Biopsy Assays (Online Course)

(based on 99 customer ratings)

Author: David J. Moffa, PhD, BCLD
Reviewer: Judi Bennett, MT, BSM

Liquid biopsy is a rapidly advancing field with a growing number of companies involved in the development of these assays for the diagnosis and stratification of cancer patients. Because liquid biopsy can potentially provide a comprehensive, real-time assessment of the whole tumor burden for an individual patient, many experts believe it has the potential to replace the standard tissue biopsy. This course will discuss the primary molecular biomarkers detected in blood via liquid biopsy assay, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes.

See all available courses »

Continuing Education Credits

  • P.A.C.E.® Contact Hours: 1 hour(s)
  • Florida Board of Clinical Laboratory Science CE - General (Molecular Pathology): 1 hour(s)

Objectives

  • Define liquid biopsy testing and review its history.
  • Compare tissue biopsy with liquid biopsy and discuss their advantages and limitations.
  • Define and describe the clinical significance of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes.
  • Review the relationship of CTCs and ctDNA in metastatic disease and understand their potential use in personalized medicine and personalized therapies for cancer.
  • Discuss the technologies involved in liquid biopsy testing and describe some leading commercial methods.

Customer Ratings

(based on 99 customer ratings)

Course Outline

  • Definition and History of Liquid Biopsy Testing
      • Liquid Biopsy: Definition
      • The History of Liquid Biopsy Assays
      • Which statement correctly identifies liquid biopsy testing?
  • Tissue Versus Liquid Biopsies: Advantages and Limitations
      • Tissue Biopsies
      • Primary Molecular Biomarkers Detected by Liquid Biopsy Assay
      • The Advantages and Limitations of Liquid Biopsies
      • For cancer patients, the tissue biopsy is a standard procedure used to pinpoint a cancer’s mutations and degree of malignancy.
      • When compared to tissue biopsy, what are the advantages of the liquid biopsy?
  • Circulating Tumor Cells (CTCs): Definition and Clinical Significance
      • Circulating Tumor Cells (CTCs): Definition and Clinical Significance
      • Circulating tumor cells (CTCs) are cells that have detached from a primary tumor and circulate in the bloodstream.
      • In patients with metastatic disease, CTCs are typically found in frequencies of what order of CTC per mL of whole blood?
  • Circulating Tumor DNA (ctDNA): Definition and Clinical Significance
      • Circulating Tumor DNA (ctDNA): Definition and Clinical Significance
      • Which of the following statements are true for circulating tumor DNA (ctDNA)? (Select all that apply.)
  • Exosomes: Definition and Clinical Significance
      • Exosomes: Definition and Clinical Significance
      • Exosomes are cell-derived vesicles in body fluids that play a key role in coagulation and are known to be released from tumors into the blood.
      • Which of the following statements is accurate regarding the clinical significance and importance of exosomes?
  • Liquid Biopsy and Personalized Medicine
      • Personalized Medicine
      • Liquid Biopsy and Personalized Medicine
      • ____________ medicine employs an individual’s genetic profile, protein makeup, and environment to prevent, diagnose, and treat disease.
  • Liquid Biopsy Technology Overview: Commercial Methods
      • Liquid Biopsy Technology Overview
      • With regard to the steps involved when performing a typical liquid biopsy assay, which of the following statements is FALSE?
      • The CELLSEARCH® CTC Test
      • The CELLSEARCH® CTC Test: Reports and Interpretation
      • Which statement is FALSE when describing the CELLSEARCH® CTC liquid biopsy test?
      • A CELLSEARCH® Test result for a metastatic breast cancer (mBC) patient was reported as eight (8) CTCs. How would this result be interpreted?
      • The test results of the CELLSEARCH® Test are reported as CTC levels that indicate a favorable versus unfavorable prognosis for certain metastatic...
      • The cobas® EGFR Mutation Test v2
      • The cobas® EGFR Mutation Test v2 has been approved by the FDA to detect EGFR mutations in non-small cell lung cancer (NSCLC) patients, as an aid ...
      • Exosome Diagnostics ExoDx™ Lung(ALK)
      • Fill in the blank: The ExoDx™ Lung(ALK) test isolates and analyzes exosomal __________ contained in blood specimens and detects EML4-ALK fusion ...
      • The ExoDx™ Lung(ALK) test is an exosome-based clinical liquid biopsy assay, designed to identify the EGFR-ALK gene fusion which can predict resp...
      • What is the exoRNeasy system used in the ExoDx™ Lung(ALK) test?
  • The Future of Liquid Biopsy Testing
      • The Future of the Liquid Biopsy Test:
      • The Future of Liquid Biopsy Test (continued):
      • Which statements are TRUE? (Select all that apply.)
  • References
      • References

Additional Information

Level of instruction: Beginning
Intended audience: Medical laboratory scientists, medical technologists, and technicians, This course is also appropriate for clinical laboratory science students and pathology residents.
Author information: David J. Moffa, PhD, BCLD has over 30 years of experience in the healthcare industry as an executive manager, clinical laboratory director, and medical laboratory scientist. He is currently a technical consultant for Kentmere Healthcare, Wilmington, DE, and until his retirement, was the Regional Director for LabCorp, Inc. He holds a PhD in medical biochemistry from the School of Medicine, West Virginia University.
Reviewer information: Judi Bennett, MT, BSM is currently a Program Director for MediaLab, Inc. in Lawrenceville, Georgia. She has over 30 years of medical laboratory experience in an acute care hospital setting as a laboratory manager, senior clinical applications specialist, point-of-care coordinator, microbiology supervisor, and generalist technologist. Judi has experience speaking at various professional conferences and is the author of numerous peer-reviewed publications.
Course description: Liquid biopsy is a rapidly advancing field with a growing number of companies involved in the development of these assays for the diagnosis and stratification of cancer patients. Because liquid biopsy can potentially provide a comprehensive, real-time assessment of the whole tumor burden for an individual patient, many experts believe it has the potential to replace the standard tissue biopsy. This course will discuss the primary molecular biomarkers detected in blood via liquid biopsy assay, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. 




Just one user? Visit LabCE.com for individual subscriptions.
biopsies shutterstock


Liver biopsy specimen


CTCs_shutterstock